SolasCure announces publication of toxicology and pre-clinical research programme as final patient is enrolled into pivotal clinical trial

Innovative Cambridge biotech company SolasCure, which is developing a revolutionary
wound cleaning technology, has published its pre-clinical results with the International
Wound Journal, showing preliminary evidence that supports its new enzymatic debridement
product for use in chronic wounds.

Leveraging biomimicry and evidence-based medicine, SolasCure, a pioneering biologics
company is developing Aurase Wound Gel, a hydrogel containing an enzyme cloned from
medical maggots that can be used to accelerate wound cleaning and support healthcare
professionals treating patients with chronic wounds.

The pre-clinical development, which included in-vitro and in-vivo applications of the Aurase
Wound Gel, has produced data that supports the significant potential for this
maggot‐derived proteolytic enzyme as a clinically effective debriding agent. Debridement,
the removal of all infected and nonviable tissue, is a crucial prerequisite for a wound to heal.

The enzyme is shown to have a good safety profile both locally and systemically, providing
for a large therapeutic window, which has permitted SolasCure under regulatory review to
test the enzyme on real patients with ulcers.

Dr Sam Bakri, Founder and CEO of SolasCure, said: “Chronic wounds pose a substantial and
growing clinical, social, and economic challenge, with increasing healthcare costs, an ageing
population, and the continued threat of diabetes and obesity across the globe.

“As SolasCure is motivated by the potential for disruptive new, life-changing technologies,
we are delighted to now share these encouraging results with the wound care community.
They are a significant milestone for SolasCure and its partners, as is the recognition from the
IWJ of the need for an effective enzymatic debrider and the potential of Aurase.”

Publication of the pre-clinical results in the IWJ comes as the final patient has been enrolled
in SolasCure’s clinical trial, which began in 2021 and involves centres across the UK, US, and
Hungary.

Results from the clinical trial are expected this year.